BRTM

9.7800.00%

3 ‘Strong Buy’ High-Risk Stocks That Could Deliver 100% or More Gains

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Aurora Innovation (AUR), SanDisk Corp. (SNDK), and Praxis Precision Medicines (PRAX) are three high-risk, high-reward stocks analysts see as having massive upside potential. Wall Street rates each a Strong Buy and projects at least 100% upside. AUR leads the pack with about 193% upside potential.

These companies operate in fast-changing markets. In such markets, investor sentiment can shift quickly as conditions change. That volatility creates significant risk, but also the potential for huge gains. This is especially true if the companies deliver on their growth strategies.

These stocks have a beta greater than two. In other words, their shares are more than twice as volatile as the broader market.

Aurora Innovation (AUR)

Aurora is a U.S. self-driving tech startup known for the Aurora Driver. This advanced platform combines hardware, software, and data services to enable self-driving. Aurora was founded in 2017 in Pittsburgh, Pennsylvania. It is now racing toward the commercial rollout of its technology.

On Wall Street, AUR has a Strong Buy consensus, with six Buys and two Holds issued over the past three months. The average AUR price target of $11.43 suggests about 193% upside ahead.

SanDisk Corp. (SNDK)

This is an American storage company. It develops and makes storage products based on NAND flash memory. This refers to non-volatile memory, meaning it stores data even when power is off. This technology is used in products such as solid-state drives, memory cards, and USB drives.

On Wall Street, SNDK carries a Strong Buy consensus, with 11 Buys and three Holds assigned over the past three months. This comes with an average price target of $2,131, suggesting about 175% upside.

Praxis Precision Medicines (PRAX)

Praxis is an American biopharma company. It makes drugs to treat brain and nerve conditions.

The company is currently seeking regulatory approval for its lead drug candidates. Relutrigine is designed to treat rare, severe seizure disorders. Similarly, ulixacaltamide is designed to treat uncontrollable shaking, especially in the hands.

On Wall Street, PRAX has a Strong Buy consensus rating. This reflects 13 Buys issued by analysts over the past three months. This comes with an average price target of $738.15, implying about 142% upside.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.